EBF:NYSEEnnis, Inc. Analysis
Data as of 2026-05-19 - not real-time
$20.39
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Ennis, Inc. is trading just above its short‑term moving average while remaining below the longer‑term average, signaling a neutral price bias. The relative strength index sits in the mid‑range, indicating neither overbought nor oversold conditions. However, the MACD has turned bearish, and declining volume suggests waning short‑term momentum. The stock’s beta is low, pointing to reduced sensitivity to overall market swings, yet the recent 30‑day volatility is elevated, reflecting price swings that could surprise investors. Fundamentally, the price‑to‑earnings multiple is well under the industry average, and the dividend yield is attractive with a payout ratio that appears sustainable. A discounted cash‑flow model implies a notable upside potential, reinforcing the undervalued narrative.
Recent earnings matched the prior year’s results, providing a measure of earnings stability. Strong operating margins and solid free cash flow underpin the ability to maintain the dividend. The balance sheet shows modest debt and ample cash, supporting financial flexibility. While technical indicators are mixed, the fundamental story—steady profitability, generous dividend, and upside valuation—makes the stock appealing for patient investors. The decreasing volume trend and neutral technical stance suggest caution in the very short term, but the longer‑term outlook remains positive.
Recent earnings matched the prior year’s results, providing a measure of earnings stability. Strong operating margins and solid free cash flow underpin the ability to maintain the dividend. The balance sheet shows modest debt and ample cash, supporting financial flexibility. While technical indicators are mixed, the fundamental story—steady profitability, generous dividend, and upside valuation—makes the stock appealing for patient investors. The decreasing volume trend and neutral technical stance suggest caution in the very short term, but the longer‑term outlook remains positive.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- bearish MACD and decreasing volume
- mid‑range RSI indicating no clear momentum
- attractive dividend yield for income‑focused investors
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF‑derived upside potential
- low beta and defensive dividend profile
- PE well below industry peers suggesting value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- consistent profitability and solid free cash flow
- sustainable dividend with reasonable payout ratio
- stable balance sheet and modest debt levels
Key Metrics & Analysis
Financial Health
Revenue Growth4.00%
Profit Margin10.86%
P/E Ratio12.3
ROE13.96%
ROA9.11%
Debt/Equity2.98
P/B Ratio1.7
Op. Cash Flow$52.7M
Free Cash Flow$25.3M
Industry P/E29.5
Technical Analysis
TrendNeutral
RSI46.3
Support$19.70
Resistance$21.14
MA 20$20.45
MA 50$20.99
MA 200$19.02
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61
Valuation
Fair Value$16.44
Target Price$24.00
Upside/Downside17.70%
GradeUndervalued
TypeValue
Dividend Yield4.90%
Risk Assessment
Beta0.50
Volatility34.31%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.